Physician profile
David Kraus
NPI 1720045339
$1,276.08
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $252 · 2021: $114 · 2022: $201 · 2023: $28.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $28.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $28.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $380.14 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $141.92 | 2019-2020 | |
| Pfizer INC. | $126.45 | 2019-2020 | |
| Novo Nordisk INC | $111.04 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $88.92 | 2019-2020 | |
| Lilly USA, LLC | $88.01 | 2019-2022 | |
| Allergan, INC. | $70.62 | 2019 | |
| Dexcom, INC. | $70.42 | 2022-2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $59.72 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.44 | 2019-2020 | |
| Amgen INC. | $22.97 | 2022 | |
| Abbvie INC. | $22.62 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.67 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.36 | 2021 | |
| Merck Sharp & Dohme LLC | $12.31 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $11.50 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kraus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.